JP2008518015A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008518015A5 JP2008518015A5 JP2007539037A JP2007539037A JP2008518015A5 JP 2008518015 A5 JP2008518015 A5 JP 2008518015A5 JP 2007539037 A JP2007539037 A JP 2007539037A JP 2007539037 A JP2007539037 A JP 2007539037A JP 2008518015 A5 JP2008518015 A5 JP 2008518015A5
- Authority
- JP
- Japan
- Prior art keywords
- compound according
- compound
- represented
- following formula
- kinase
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 150000001875 compounds Chemical class 0.000 claims 93
- 229910052760 oxygen Inorganic materials 0.000 claims 33
- 229910052757 nitrogen Inorganic materials 0.000 claims 28
- 229910052739 hydrogen Inorganic materials 0.000 claims 23
- 239000001257 hydrogen Substances 0.000 claims 22
- 125000000217 alkyl group Chemical group 0.000 claims 21
- 239000000203 mixture Substances 0.000 claims 13
- 150000002431 hydrogen Chemical class 0.000 claims 12
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 10
- 125000000623 heterocyclic group Chemical group 0.000 claims 10
- 229910052717 sulfur Inorganic materials 0.000 claims 9
- 125000004432 carbon atom Chemical group C* 0.000 claims 8
- 150000003839 salts Chemical class 0.000 claims 6
- 108091000080 Phosphotransferase Proteins 0.000 claims 5
- 102000020233 phosphotransferase Human genes 0.000 claims 5
- 125000000547 substituted alkyl group Chemical group 0.000 claims 5
- 125000002837 carbocyclic group Chemical group 0.000 claims 4
- 125000003107 substituted aryl group Chemical group 0.000 claims 4
- 101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 claims 3
- 101000934996 Homo sapiens Tyrosine-protein kinase JAK3 Proteins 0.000 claims 3
- 108090000744 Mitogen-Activated Protein Kinase Kinases Proteins 0.000 claims 3
- 102000004232 Mitogen-Activated Protein Kinase Kinases Human genes 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 108010055723 PDGF receptor tyrosine kinase Proteins 0.000 claims 3
- 102000003923 Protein Kinase C Human genes 0.000 claims 3
- 108090000315 Protein Kinase C Proteins 0.000 claims 3
- 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 claims 3
- 102100025387 Tyrosine-protein kinase JAK3 Human genes 0.000 claims 3
- 125000003342 alkenyl group Chemical group 0.000 claims 3
- 125000000304 alkynyl group Chemical group 0.000 claims 3
- 108010056708 bcr-abl Fusion Proteins Proteins 0.000 claims 3
- 229910052794 bromium Inorganic materials 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 229910052801 chlorine Inorganic materials 0.000 claims 3
- 239000000460 chlorine Substances 0.000 claims 3
- 229910052731 fluorine Inorganic materials 0.000 claims 3
- 125000005843 halogen group Chemical group 0.000 claims 3
- 108010042209 insulin receptor tyrosine kinase Proteins 0.000 claims 3
- 229910052740 iodine Inorganic materials 0.000 claims 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 3
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 2
- 102000001301 EGF receptor Human genes 0.000 claims 2
- 108060006698 EGF receptor Proteins 0.000 claims 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 2
- 241001465754 Metazoa Species 0.000 claims 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 239000011737 fluorine Substances 0.000 claims 2
- 238000001727 in vivo Methods 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 239000011630 iodine Substances 0.000 claims 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 125000006239 protecting group Chemical group 0.000 claims 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 1
- 125000006736 (C6-C20) aryl group Chemical class 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical group OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 125000002947 alkylene group Chemical group 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 238000013160 medical therapy Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 125000004437 phosphorous atom Chemical group 0.000 claims 1
- 125000000168 pyrrolyl group Chemical group 0.000 claims 1
- 102000027426 receptor tyrosine kinases Human genes 0.000 claims 1
- 108091008598 receptor tyrosine kinases Proteins 0.000 claims 1
- 0 CCCC=C(*C(C)(*)*)C(*)(*)C(C)(C(C)N)*(*)* Chemical compound CCCC=C(*C(C)(*)*)C(*)(*)C(C)(C(C)N)*(*)* 0.000 description 6
- YNQLUTRBYVCPMQ-UHFFFAOYSA-N CCc1ccccc1 Chemical compound CCc1ccccc1 YNQLUTRBYVCPMQ-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US62281104P | 2004-10-26 | 2004-10-26 | |
| US62299204P | 2004-10-26 | 2004-10-26 | |
| US62294304P | 2004-10-26 | 2004-10-26 | |
| US62309804P | 2004-10-26 | 2004-10-26 | |
| US62294204P | 2004-10-26 | 2004-10-26 | |
| US62296004P | 2004-10-26 | 2004-10-26 | |
| US62288104P | 2004-10-26 | 2004-10-26 | |
| PCT/US2005/038348 WO2006047507A2 (en) | 2004-10-26 | 2005-10-25 | Phosphonate substituted kinase inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008518015A JP2008518015A (ja) | 2008-05-29 |
| JP2008518015A5 true JP2008518015A5 (ru) | 2008-11-13 |
Family
ID=36228375
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007539037A Withdrawn JP2008518015A (ja) | 2004-10-26 | 2005-10-25 | ホスホネート置換キナーゼ阻害剤 |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP1809299A2 (ru) |
| JP (1) | JP2008518015A (ru) |
| AU (1) | AU2005299504A1 (ru) |
| CA (1) | CA2585281A1 (ru) |
| WO (1) | WO2006047507A2 (ru) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106749223B (zh) * | 2015-11-25 | 2019-12-20 | 中国科学院广州生物医药与健康研究院 | 酪氨酸激酶抑制剂及其制备方法和用途 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1610793A2 (en) * | 2003-03-25 | 2006-01-04 | Vertex Pharmaceuticals Incorporated | Thiazoles useful as inhibitors of protein kinases |
| US20060069101A1 (en) * | 2004-09-27 | 2006-03-30 | Kim Kyoung S | Prodrugs of protein tyrosine kinase inhibitors |
-
2005
- 2005-10-25 WO PCT/US2005/038348 patent/WO2006047507A2/en active Application Filing
- 2005-10-25 CA CA002585281A patent/CA2585281A1/en not_active Abandoned
- 2005-10-25 AU AU2005299504A patent/AU2005299504A1/en not_active Abandoned
- 2005-10-25 EP EP05812489A patent/EP1809299A2/en not_active Withdrawn
- 2005-10-25 JP JP2007539037A patent/JP2008518015A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007529421A5 (ru) | ||
| JP4959900B2 (ja) | 抗ウイルスピリミジンヌクレオシド類 | |
| AU2014372166B2 (en) | Pharmaceutical combinations | |
| ES2547916T3 (es) | Terapia de combinación de inhibidores de mTOR/JAK | |
| TW200418837A (en) | Combination administration of an indolinone with a chemotherapeutic agent for cell proliferation disorders | |
| JP2006524710A5 (ru) | ||
| JP2017511360A5 (ru) | ||
| TWI633887B (zh) | 用於預防及／或治療多囊性腎臟病之藥物 | |
| JP2013512903A5 (ru) | ||
| JP2008535902A5 (ru) | ||
| JP2008514732A5 (ru) | ||
| US11524009B2 (en) | Combination comprising at least one spliceosome modulator and at least one inhibitor chosen from BCL2 inhibitors, BCL2/BCLxL inhibitors, and BCLxL inhibitors and methods of use | |
| JP2006501201A5 (ru) | ||
| JP6014142B2 (ja) | Ｎ−ヒドロキシ−４−｛２−［３−（ｎ，ｎ−ジメチルアミノメチル）ベンゾフラン−２−イルカルボニルアミノ］エトキシ｝ベンズアミドの投与に関するスキーム | |
| ES2698363T3 (es) | Composiciones de oxprenolol para tratar el cáncer | |
| KR101401220B1 (ko) | 방사선 치료 증강제 | |
| JP2016525104A5 (ru) | ||
| JP2011518168A5 (ru) | ||
| TW200927127A (en) | Agent for overcoming resistance to anti-cancer agent | |
| RU2011150619A (ru) | Комбинация ингибитора фосфоинозитид-3-киназы и противодиабетического соединения | |
| BR112020009290A2 (pt) | derivados de pirimidina para a prevenção e tratamento de infecções bacterianas | |
| KR20130103650A (ko) | (ｅ)-4-카복시스티릴-4-클로로벤질설폰의 개선된 안정한 수성 제형 | |
| BRPI0608806A2 (pt) | compostos quìmicos, composição farmacêutica e uso de compostos quìmicos | |
| JP2016530208A5 (ru) | ||
| JP7493503B2 (ja) | Ｍｃｌ－１阻害剤とミドスタウリンとの組み合わせ、その使用及び医薬組成物 |